Runing Cui

My research focuses on developing a gelatin-based tissue-engineered hydrogel platform to investigate how tumor microenvironmental cues and cellular heterogeneity drive temozolomide (TMZ) resistance in glioblastoma (GBM). This system enables the study of mechanisms underlying therapeutic failure and supports the evaluation of TMZ analogs that can target invasive GBM populations independent of MGMT status.